Balancing The Use Of Cost-Effectiveness Analysis Across All Types Of Health Care Innovations

While CEAs of pharmaceutical interventions are vital, the disproportionate application of CEA to certain types of interventions can lead to less efficient use of health care dollars overall.

April 14, 2017

Value Frameworks For Rare Diseases: Should They Be Different?

Despite increases in rare disease treatments attributable to the Orphan Drug Act, the economic value of rare disease treatments has come under increasing scrutiny. Assessing the value of treatments for rare diseases presents several unique challenges that should be considered by policymakers.

April 12, 2017

Scott Gottlieb’s FDA Commissioner Confirmation Hearing: Remarkably Unremarkable

In a presidential administration whose confirmation hearings have sparked more than a few contentious moments, FDA Commissioner-designate Scott Gottlieb’s confirmation hearing was remarkable for how unremarkable it was. But to say the hearing was uneventful is not to say that it was uninteresting.

April 7, 2017

A Strategy For Lowering Brand Drug Prices: Patent Buyouts And Licensing

Why does competition among brand drugs often fail to reduce prices? Creating nonprofit entities to purchase the intellectual property rights to any one of several competing brand drugs and license those rights to multiple generic manufacturers could both increase competition and lower prices.

April 5, 2017

Overcoming Challenges Of Outcomes-Based Contracting For Pharmaceuticals: Early Lessons From The Genentech–Priority Health Pilot

Scientific investments have led to breakthroughs not previously imaginable. However, treating people with serious diseases such as cancer is expensive. The Genentech–Priority Health outcomes-based pilot sought to move beyond the transactional nature of payer–pharma relationships to build a...

April 3, 2017

Strategies To Address The Challenges Of Outcomes-Based Pricing Agreements For Pharmaceuticals

Outcomes-based pricing agreements may both improve access to treatments for patients who derive the greatest benefits from them and strengthen pharmaceutical companies’, clinicians’, and insurers’ interest in discouraging the use of ineffective therapies. However, stakeholders are missing...

April 3, 2017

Modernizing And Strengthening Existing Laws To Control Drug Costs

If President Trump truly intends to control drug costs, fixing drug pricing formulas and enhancing existing penalties could reduce costs for both public and private payers.

March 31, 2017

Prescription Drug Regulation, Promotion, And Advocacy Has Gotten More Vexing In 2017

Early 2017 has been one of the most interesting and challenging times for anyone concerned with medication regulation and evidence-based prescribing — as well as for the patients and health care professionals who will be so heavily impacted recent policy changes.

March 23, 2017

For Rare Disease Patients, A Pathway To Hundreds Of New Therapies

Most rare disease patients never have the chance to receive a repurposed, potentially life-saving treatment while others receive off-label treatments with poor clinical data that were destined to fail from the start. The OPEN ACT would begin to fix this serious gap in the drug development landscape.

March 21, 2017

A Better Balance Between Accelerated Access And High-Priced New Drugs: A New Conditional Approval Option

A new form of “conditional approval” could accelerate the approval of new drugs and, at the same time, take at least a small step towards reducing the costs of potentially life-saving drugs.

March 20, 2017